The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress.
about
Pharmacological treatment of anxiety disorders: current treatments and future directionsEndogenous Opioids: The Downside of Opposing Stress.Endogenous opioids: opposing stress with a cost.Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal modelsPersistent anxiolytic affects after chronic administration of the CRF₁ receptor antagonist R121919 in rats.Pharmacotherapy of PTSD: premises, principles, and prioritiesLocomotor response to novelty as a predictor of reactivity to aversive stimuli in the ratRole of corticotropin releasing factor in anxiety disorders: a translational research perspectiveCorticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.Role of innate and drug-induced dysregulation of brain stress and arousal systems in addiction: Focus on corticotropin-releasing factor, nociceptin/orphanin FQ, and orexin/hypocretin.Corticotropin releasing factor receptor antagonists for major depressive disorder.Protracted withdrawal from alcohol and drugs of abuse impairs long-term potentiation of intrinsic excitability in the juxtacapsular bed nucleus of the stria terminalis.The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in ratsCortisol response to individualised graded insulin infusions: a reproducible biomarker for CNS compounds inhibiting HPA activation.Effects of a post-shock injection of the kappa opioid receptor antagonist norbinaltorphimine (norBNI) on fear and anxiety in rats.Lithium, but not fluoxetine or the corticotropin-releasing factor receptor 1 receptor antagonist R121919, increases cell proliferation in the adult dentate gyrus.Corticotropin-Releasing Factor Receptor-1 Antagonism Reduces Oxidative Damage in an Alzheimer’s Disease Transgenic Mouse Model.Endocrine disturbances in depression.Depressive and cardiovascular disease comorbidity in a rat model of social stress: a putative role for corticotropin-releasing factor.A corticotropin-releasing factor receptor antagonist improves urodynamic dysfunction produced by social stress or partial bladder outlet obstruction in male rats.Effects of CB1 and CRF1 receptor antagonists on binge-like eating in rats with limited access to a sweet fat diet: lack of withdrawal-like responses.Corticotropin-releasing factor-1 receptor antagonists decrease heroin self-administration in long- but not short-access rats.Modulation of dendritic differentiation by corticotropin-releasing factor in the developing hippocampus.Central infusion of ovine CRF (oCRF) potentiates defensive behaviors in CD-1 mice in the Mouse Defense Test Battery (MDTB).Angiotensin type 1a receptors in the paraventricular nucleus of the hypothalamus control cardiovascular reactivity and anxiety-like behavior in male mice.Cyclotides Isolated from an Ipecac Root Extract Antagonize the Corticotropin Releasing Factor Type 1 Receptor.Altered serotonergic neurotransmission but normal hypothalamic-pituitary-adrenocortical axis activity in mice chronically treated with the corticotropin-releasing hormone receptor type 1 antagonist NBI 30775.Consequences of chronic social stress on behaviour and vasopressin gene expression in the PVN of DBA/2OlaHsd mice--influence of treatment with the CRHR1-antagonist R121919/NBI 30775.Distribution of Corticotrophin-Releasing Factor Type 1 Receptor-Like Immunoreactivity in the Rat Pituitary.
P2860
Q26851461-DBDAA9CA-1F84-4F42-A298-5A8E50F119E9Q30394985-F85E0815-C0F2-4678-B6C6-9407A475C4DEQ30408911-3D1D526E-BFCD-4157-B845-81A9ABAE7A33Q30466695-CB31B9BC-7022-4BE1-BA7B-00B511A55AB1Q30467178-D022A522-89E1-41B7-AE91-18B3FDE3D0F8Q30479154-85DD9A8E-F2A1-4518-A592-60D1BF6CA954Q30494343-A21E2737-1576-437E-BFF0-00ABF7718A78Q30498732-6257AEC6-86C1-4585-9D1B-2E3552229DD1Q30502566-EF14CB7D-24D4-42E8-B619-7093BAE874D4Q33643476-FE4BFC46-ABB2-4B27-9932-B68790E2F038Q33843656-9F1A6AAD-072A-462E-A1A8-66B1F3EBCC84Q34122457-BEF1BEA2-9D19-4DF4-84CB-47233B8990A5Q34226624-40C85222-B894-4FE6-A8AF-5CBDA2604F06Q34457448-C3BCCBBB-D561-4ADA-9BD2-07A890FB5CA6Q34482680-361FF6F4-45D7-4809-A626-B24189023F49Q34715718-44DF71DD-867F-45D0-AC36-33C4CFE3104FQ35801845-B213B926-009E-49A5-B062-0D733A480718Q36091591-4CAF0859-1DAD-4008-A88A-CF8A4E3DDB27Q36731712-C2646D4F-42EC-4AE1-8DF8-804523841078Q36923889-BFF4FDE9-E934-4E1D-B263-F8D0A2C7C295Q37302152-065D61FA-1C3B-461D-BC9C-BDB456C4D71DQ37357463-800EE8CF-8742-4D42-AC4E-B29805BC0AC5Q37595578-DE29B468-3450-4F08-BA3E-A51417D755BBQ39775679-5553C8F6-1A3F-41B7-8535-76D642D0DD96Q41874539-CA816C11-3BD6-41B0-AB9E-36908E952D1DQ42369922-2EE8CA7F-4B8A-4729-A03E-A8C73DB9E95FQ42446037-D910B633-79ED-4C65-814A-01553B353BF1Q46565067-E0B01752-EDBF-485A-A994-301482B40E51Q47852668-26C1B574-35D7-4E24-9A0C-FF09EB16278C
P2860
The corticotropin-releasing factor1 receptor antagonist R121919 attenuates the behavioral and endocrine responses to stress.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
The corticotropin-releasing fa ...... endocrine responses to stress.
@en
The corticotropin-releasing fa ...... endocrine responses to stress.
@nl
type
label
The corticotropin-releasing fa ...... endocrine responses to stress.
@en
The corticotropin-releasing fa ...... endocrine responses to stress.
@nl
prefLabel
The corticotropin-releasing fa ...... endocrine responses to stress.
@en
The corticotropin-releasing fa ...... endocrine responses to stress.
@nl
P2093
P356
P1476
The corticotropin-releasing fa ...... endocrine responses to stress.
@en
P2093
Charles B Nemeroff
David A Gutman
K V Thrivikraman
Kelly H Skelton
Michael J Owens
P304
P356
10.1124/JPET.102.042788
P407
P577
2003-02-01T00:00:00Z